MX2023003245A - Derivados de amina novedosos. - Google Patents
Derivados de amina novedosos.Info
- Publication number
- MX2023003245A MX2023003245A MX2023003245A MX2023003245A MX2023003245A MX 2023003245 A MX2023003245 A MX 2023003245A MX 2023003245 A MX2023003245 A MX 2023003245A MX 2023003245 A MX2023003245 A MX 2023003245A MX 2023003245 A MX2023003245 A MX 2023003245A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- amine derivative
- formula
- dyrk
- represented
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020157398 | 2020-09-18 | ||
| JP2021122893 | 2021-07-28 | ||
| PCT/JP2021/034327 WO2022059779A1 (ja) | 2020-09-18 | 2021-09-17 | アミン誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023003245A true MX2023003245A (es) | 2023-04-11 |
Family
ID=80776131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023003245A MX2023003245A (es) | 2020-09-18 | 2021-09-17 | Derivados de amina novedosos. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230365589A1 (https=) |
| EP (1) | EP4215534A4 (https=) |
| JP (2) | JP7706775B2 (https=) |
| KR (1) | KR20230069162A (https=) |
| CN (1) | CN116209441A (https=) |
| AU (1) | AU2021343770A1 (https=) |
| BR (1) | BR112023003807A2 (https=) |
| CA (1) | CA3191617A1 (https=) |
| MX (1) | MX2023003245A (https=) |
| WO (1) | WO2022059779A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023008470A1 (ja) * | 2021-07-28 | 2023-02-02 | 住友ファーマ株式会社 | 縮環アミン誘導体 |
| WO2025170029A1 (ja) * | 2024-02-09 | 2025-08-14 | カルナバイオサイエンス株式会社 | ジヒドロキナゾリノン誘導体 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20020084116A (ko) * | 2000-02-07 | 2002-11-04 | 애보트 게엠베하 운트 콤파니 카게 | 2-벤조티아졸릴 우레아 유도체 및 이의 단백질 키나제억제제로서의 용도 |
| EP1679308B1 (en) | 2003-10-15 | 2013-07-24 | Ube Industries, Ltd. | Novel indazole derivative |
| WO2008021338A2 (en) * | 2006-08-15 | 2008-02-21 | Wyeth | Tricyclic oxazolidone derivatives useful as pr modulators |
| JP2010163361A (ja) | 2007-04-27 | 2010-07-29 | Dainippon Sumitomo Pharma Co Ltd | キノリン誘導体 |
| KR20100010894A (ko) | 2008-07-23 | 2010-02-02 | 가부시키가이샤 키노파마 | Ｄｙｒｋ를 저해하는 화합물을 함유하는 의약 조성물 |
| US8470835B2 (en) | 2009-01-13 | 2013-06-25 | Glaxo Group Limited | Pyrimidinecarboxamide derivatives as inhibitors of Syk kinase |
| TW201039825A (en) | 2009-02-20 | 2010-11-16 | Astrazeneca Ab | Cyclopropyl amide derivatives 983 |
| CN102712601A (zh) * | 2009-11-12 | 2012-10-03 | 赛尔维他股份公司 | 化合物、其制备方法、药物组合物、化合物的用途、用于调节或调控丝氨酸/苏氨酸激酶的方法以及丝氨酸/苏氨酸激酶调节剂 |
| CA2816219C (en) | 2010-11-01 | 2019-10-29 | Portola Pharmaceuticals, Inc. | Nicotinamides as syk modulators |
| UY34200A (es) | 2011-07-21 | 2013-02-28 | Bayer Ip Gmbh | 3-(fluorovinil)pirazoles y su uso |
| US9446044B2 (en) | 2011-08-19 | 2016-09-20 | Diaxonhit | DYRK1 inhibitors and uses thereof |
| WO2013043002A1 (en) | 2011-09-23 | 2013-03-28 | Yuhan Corporation | Imide-containing benzothiazole derivative or its salt and pharmaceutical composition comprising the same |
| KR101916443B1 (ko) | 2012-07-26 | 2018-11-08 | 글락소 그룹 리미티드 | Pad4 억제제로서의 2-(아자인돌-2-일) 벤즈이미다졸 |
| RS63405B1 (sr) | 2013-10-25 | 2022-08-31 | Blueprint Medicines Corp | Inhibitori receptora faktora rasta fibroblasta |
| JP2015107945A (ja) | 2013-12-05 | 2015-06-11 | 国立大学法人京都大学 | 神経新生に関する化合物及び医薬組成物 |
| GB201401886D0 (en) * | 2014-02-04 | 2014-03-19 | Lytix Biopharma As | Neurodegenerative therapies |
| JP2017516850A (ja) | 2014-05-23 | 2017-06-22 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｊａｋ阻害剤である５−クロロ−２−ジフルオロメトキシフェニルピラゾロピリミジン化合物 |
| WO2016044641A2 (en) | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Carm1 inhibitors and uses thereof |
| GB201617339D0 (en) | 2016-10-12 | 2016-11-23 | Lytix Biopharma As | Therapeutic compounds |
| CN109206537B (zh) | 2018-10-10 | 2021-04-09 | 华熙生物科技股份有限公司 | 一种乙酰化透明质酸钠的制备方法及其应用 |
| US20230138851A1 (en) * | 2020-01-30 | 2023-05-04 | Carna Biosciences, Inc. | Novel alkyne derivatives |
-
2021
- 2021-09-17 EP EP21869461.0A patent/EP4215534A4/en active Pending
- 2021-09-17 WO PCT/JP2021/034327 patent/WO2022059779A1/ja not_active Ceased
- 2021-09-17 US US18/026,187 patent/US20230365589A1/en active Pending
- 2021-09-17 CA CA3191617A patent/CA3191617A1/en active Pending
- 2021-09-17 BR BR112023003807A patent/BR112023003807A2/pt not_active Application Discontinuation
- 2021-09-17 KR KR1020237012416A patent/KR20230069162A/ko active Pending
- 2021-09-17 MX MX2023003245A patent/MX2023003245A/es unknown
- 2021-09-17 AU AU2021343770A patent/AU2021343770A1/en active Pending
- 2021-09-17 CN CN202180063922.5A patent/CN116209441A/zh active Pending
- 2021-09-17 JP JP2022550631A patent/JP7706775B2/ja active Active
-
2025
- 2025-06-25 JP JP2025106969A patent/JP2025134941A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021343770A9 (en) | 2024-09-12 |
| KR20230069162A (ko) | 2023-05-18 |
| JP2025134941A (ja) | 2025-09-17 |
| JP7706775B2 (ja) | 2025-07-14 |
| EP4215534A1 (en) | 2023-07-26 |
| US20230365589A1 (en) | 2023-11-16 |
| EP4215534A4 (en) | 2024-10-02 |
| BR112023003807A2 (pt) | 2023-03-28 |
| CA3191617A1 (en) | 2022-03-24 |
| CN116209441A (zh) | 2023-06-02 |
| JPWO2022059779A1 (https=) | 2022-03-24 |
| TW202227459A (zh) | 2022-07-16 |
| AU2021343770A1 (en) | 2023-05-18 |
| WO2022059779A1 (ja) | 2022-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA521422143B1 (ar) | 15-pgdh مثبط | |
| ZA202206923B (en) | New methylquinazolinone derivatives | |
| ZA202401567B (en) | Ring-modified proline short peptide compound and use thereof | |
| ZA202308002B (en) | Pyrimidopyran compound | |
| IS6902A (is) | N-setin heterósýklísk NMDA/NR2B mótlyf sem ekki eru arýl | |
| EA200400981A1 (ru) | Новые гетероциклические соединения, активные в качестве ингибиторов бета-лактамаз | |
| TW200716576A (en) | Heterocyclic derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | |
| ZA202213152B (en) | Novel acid secretion inhibitor and use thereof | |
| TW200642689A (en) | Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient | |
| MX2020002824A (es) | Aminas beta-hidroxi heterociclicas y su uso en el tratamiento de la hiperglucemia. | |
| MX2023003245A (es) | Derivados de amina novedosos. | |
| MX2021003232A (es) | Inhibidores de o-glicoproteina-2-acetamido-2-desoxi-3-d-glucopiran osidasa. | |
| MXPA05011176A (es) | Derivados de carboxamida como agentes antidiabeticos. | |
| CR20220255A (es) | Inhibidores de egfr | |
| MX2025013480A (es) | Compuestos heterocíclicos que contienen nitrógeno y uso de los mismos | |
| TN2021000025A1 (en) | Novel heterocyclic amine derivative and pharmaceutical composition comprising same | |
| PH12022551134A1 (en) | Therapeutic agent and prophylactic agent for functional gastrointestinal disorders and xerostomia | |
| SG11201810725WA (en) | Novel β-lactamase inhibitors | |
| CR20230218A (es) | Nuevos derivados de indazol acetileno | |
| JOP20200327A1 (ar) | مركبات سيانوتريازول واستخداماتها | |
| SG11201907945YA (en) | Azetidine derivative | |
| MX2024002674A (es) | Derivados de tiadiazolona utiles como activadores de ampk. | |
| PH12022550860A1 (en) | 5-oxa-2-azaspiro[3.4]octane derivatives as m4 agonists | |
| ZA202401345B (en) | Polypeptide drug conjugate having novel structure and application thereof | |
| PL1845780T3 (pl) | Zastosowanie pochodnych metylofenidatu |